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Abstract
To assess the clinical relevance of transgenic and patient-derived xenograft models of
adamantinomatous craniopharyngioma (ACP) using serial magnetic resonance imaging
(MRI) and high resolution post-mortem microcomputed tomography (l-CT), with
correlation with histology and human ACP imaging. The growth patterns and radiological
features of tumors arising in Hesx1Cre/1;Ctnnb1lox(ex3)/1 transgenic mice, and of patient-
derived ACP xenografts implanted in the cerebral cortex, were monitored longitudinally in
vivo with anatomical and functional MRI, and by ex vivo l-CT at study end. Pathological
correlates with hematoxylin and eosin stained sections were investigated. Early enlargement
and heterogeneity of Hesx1Cre/1;Ctnnb1lox(ex3)/1 mouse pituitaries was evident at initial
imaging at 8 weeks, which was followed by enlargement of a solid tumor, and development
of cysts and hemorrhage. Tumors demonstrated MRI features that recapitulated those of
human ACP, speciﬁcally, T1-weighted signal enhancement in the solid tumor component
following Gd-DTPA administration, and in some animals, hyperintense cysts on FLAIR and
T1-weighted images. Ex vivo l-CT correlated with MRI ﬁndings and identiﬁed smaller cysts,
which were conﬁrmed by histology. Characteristic histological features, including wet
keratin and calciﬁcation, were visible on l-CT and veriﬁed by histological sections of
patient-derived ACP xenografts. The Hesx1Cre/1;Ctnnb1lox(ex3)/1 transgenic mouse model
and cerebral patient-derived ACP xenografts recapitulate a number of the key radiological
features of the human disease and provide promising foundations for in vivo trials of novel
therapeutics for the treatment of these tumors.
INTRODUCTION
Adamantinomatous craniopharyngioma (ACP) is the most common
tumor of the sellar region in childhood, accounting for approxi-
mately 1.2–4% of pediatric intracranial tumors. Peak incidence
occurs at 5–9 years with a second peak in adults aged 45–60 years
(20, 21). Although appearing histopathologically benign and classi-
ﬁed by the World Health Organisation as grade I (17), ACP is often
clinically aggressive, demonstrating invasion of the hypothalamus
and visual pathways, and destruction of the pituitary. Current treat-
ment strategies involve surgery, radiotherapy and cystic drainage.
Although associated with good 5 year survival, patients frequently
suffer severe long term morbidity, with pituitary and hypothalamic
dysfunction, visual impairment and poor quality of life (20).
ACP is an epithelial lesion thought to arise from Rathke’s pouch,
the embryonic primordium of the anterior pituitary, and is charac-
terized by the formation of a peripheral basal layer of palisading
epithelium, loose aggregates of stellate cells, nodules of “wet
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keratin” (anuclear “ghost cells”), whorl-like cell clusters and cysts
containing high levels of protein, cholesterol and calciﬁcation (19).
ACPs present as variably cystic/solid tumors in the intrasellar and/
or suprasellar region by both magnetic resonance imaging (MRI)
and computed tomography (CT) (10). Calciﬁcation, present in over
90% of ACPs, is detectable by CT, which is therefore widely used
for differential diagnosis following initial identiﬁcation by MRI
(29).
Mutations in CTNNB1, which encodes b-catenin, predicted to
cause the over-activation of the WNT pathway, have been identi-
ﬁed in the majority of human ACP samples analyzed (7, 9, 15, 24).
Unusually, nuclear-cytoplasmic localization of activated b-catenin
is found in only a small proportion of tumor cells, either as small
cell clusters, which broadly correlate with epithelial whorls, or oth-
erwise dispersed in a minority of cells throughout the tumor (9,
11). We have recently described the 3D structure of human ACP
using high resolution micro-CT (m-CT) imaging (2), and corrobo-
rated the presence of clusters at the leading invasive edge of tissue
invasion (8, 26).
Expression of oncogenic b-catenin in the developing pituitary in
Hesx1Cre/1;Ctnnb1lox(ex3)/1 mice results in tumors resembling
human ACP at the histological and molecular levels (11). Despite
activation of b-catenin in all pituitary cells in this model, nuclear
accumulation is only observed in small clusters of cells, analogous
to human clusters. Previous studies have shown that these mice
have a median survival of approximately 11 weeks, with a remark-
able variability, and at the time of death exhibit large cystic masses
beneath the brain (11). To date, the kinetics of tumor development
in this transgenic mouse model of ACP has not been studied.
A patient-derived xenograft model of ACP has also been estab-
lished through placement of uncultivated human tumor tissue into
the cerebral hemisphere of immunodeﬁcient mice (26). Lesions
propagated in this manner show comparable tissue architecture and
express similar immunohistochemical markers to the patient
tumors, including whorl-like cell clusters with nuclear b-catenin
accumulation and activated EGFR (26).
In this study we have further characterized tumors arising in the
Hesx1Cre/1;Ctnnb1lox(ex3)/1 transgenic mouse model of ACP in vivo,
describing both their radiological features and patterns of growth
through longitudinal multiparametric MRI imaging. Using l-CT we
have assessed both these murine tumors, and cerebral patient-
derived ACP xenografts, ex vivo in 3D at high resolution. Compari-
son with clinical imaging and pathology demonstrated that both
these models recapitulate the radiological features of human ACP.
MATERIALS AND METHODS
Hesx1Cre/1;Ctnnb1lox(ex3)/1 transgenic model of
ACP
Hesx1Cre/1;Ctnnb1lox(ex3)/1 mice have been described previously (11).
All experiments were performed in accordance with the local Animal
Welfare and Ethical Review Board, the UK Home Ofﬁce Animals
(Scientiﬁc Procedures) Act 1986, the United Kingdom National Can-
cer Research Institute guidelines for the welfare of animals in cancer
research (30) and the ARRIVE (animal research: reporting in vivo
experiments) guidelines (16). Eighteen Hesx1Cre/1;Ctnnb1lox(ex3)/1
and four wildtype control mice were assessed in this study.
Patient-derived ACP xenograft model
A fresh surgical specimen from a 56 year old male patient with
ACP was retrieved from the Department of Neurosurgery at the
University Hospital Erlangen. Tumor tissue was veriﬁed and classi-
ﬁed as previously and was found to bear a TCT(Ser)>TGT(Cys)
mutation in codon 33 of CTNNB1 but no mutation in exon 15 of
BRAF (13, 26). A declaration of consent for the patient is available,
approved by the local ethics committee of the Friedrich-Alexander-
Universit€at Erlangen-N€urnberg. Procedures were conducted in
accordance to the Declaration of Helsinki.
All experiments performed were authorized by the local govern-
ment (Regierung von Unterfranken, Germany, Ref.-No. 54–
2532.01–25/14) in accordance with the animal protection act. The
surgical specimen was divided and implanted into the right cerebral
hemisphere of four female NMRI-Fox1nu/Fox1nu mice (Janvier
Labs, Le Genest-Saint-Isle, France). Anesthetized mice were
secured in a stereotactic frame (Bilaney Consultants, D€usseldorf,
Germany), a 5mm incision made in the scalp and a 1mm burr hole
drilled 3mm lateral to the bregma. A piece of uncultivated tumor
tissue (1–8 mm3) was inserted through the hole using a sterile can-
nula and the skin closed using a suture (ETHILON*II 4–0, Ethicon,
Norderstedt, Germany). Analgesic (1 mg/g metamizole, Ratio-
pharm, Ulm, Germany) was added to the drinking water for 3 days
following the procedure. Body weight and animal behavior were
monitored daily (26).
Magnetic resonance imaging
1H MRI of Hesx1Cre/1;Ctnnb1lox(ex3)/1 mice was performed on a
7T horizontal bore microimaging system (Bruker, Ettlingen, Ger-
many) using a 30 mm birdcage coil and 1 mm thick slices acquired
over a 25 mm 3 25 mm ﬁeld of view (FOV). Imaging was per-
formed fortnightly from approximately 8 weeks of age, increasing
to weekly once tumor progression was established. Anesthesia was
induced with either 3% isoﬂurane in 100% oxygen (1 L/min) and
maintained with 1% isoﬂurane (for longitudinal screening/monitor-
ing), or a 10 mL/kg intraperitoneal injection of fentanyl citrate
(0.315 mg/mL) plus ﬂuanisone [10 mg/mL (Hypnorm; Janssen
Pharmaceutical Ltd. High Wycombe, UK)], midazolam [5 mg/mL
(Hypnovel; Roche, Burgess Hill, UK)], and sterile water (1:1:2)
(for functional MRI at study end). A lateral tail vein was cannulated
with a 27G butterﬂy catheter (Venisystems, Hospira, Royal
Leamington Spa, UK) if remote administration of Gd-DTPA
(Magnevist; Schering, Berlin, Germany) was required. Core body
temperature was maintained by warm air blown through the magnet
bore.
Magnetic ﬁeld homogeneity was ﬁrst optimized by shimming
over the entire brain using an automated shimming routine (FAST-
MAP). Anatomical multi-slice contiguous T2-weighted RARE
images (TR54500 ms, TEeff5 36 ms, 8 averages, 256 3 256
matrix, pixel size5 98 mm 3 98 mm) were then acquired to moni-
tor tumor development and for subsequent volumetric analysis.
Fluid attenuated inversion recovery (FLAIR; TR518 000 ms,
TEeff5 35 ms, TI5 2100 ms, 4 averages, ﬂip angle5 1258, 128 3
128 matrix) and T1-weighted (TR5 1300 ms, TE5 7.5 ms, 4 aver-
ages, 256 3 256 matrix) images were also acquired. At study end,
echo-planar diffusion-weighted imaging (EPI-DWI) was used to
determine the apparent diffusion coefﬁcient (ADC) (5), and either
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T1-weighted images acquired before and 1 minute after intravenous
administration of 0.1 mmol/kg Gd-DTPA (Magnevist, Schering),
or dynamic contrast-enhanced (DCE) MRI (4) was used to assess
patent tumor vasculature.
MRI of nude mice bearing cerebral patient-derived ACP xeno-
grafts was performed between 124 and 130 days after tumor
implantation, at which time successful tumor engraftment had pre-
viously been conﬁrmed histologically (26), under isoﬂurane anes-
thesia, on a 7T horizontal bore microimaging system (Bruker,
Ettlingen, Germany) equipped with a dedicated mouse brain coil
and an animal monitoring system. T2-weighted images (TR5 2370
ms, TE5 41 ms, slice thickness5 0.7 mm, FOV5 24 mm 3
38 mm, 210 3 320 matrix, pixel size5 119 mm 3 119 mm) and
T1-weighted contrast-enhanced images prior to and following intra-
venous administration of 0.1 mmol/kg gadobutrol (Gadovist, Bayer
Vital, Leverkusen, Germany) (TR5 500 ms, TE5 9 ms, slice
thickness5 0.7 mm, FOV5 24 mm 3 28 mm, 448 3 512 matrix,
pixel size5 55 mm3 55 mm) were acquired.
MRI data analysis
Volumetric analysis was performed using segmentation from
regions of interest (ROIs) drawn on T2-weighted images. Parameter
estimation was undertaken using a Bayesian maximum a posteriori
algorithm, which took into account the Rician distribution of noise
in magnitude MR data to provide unbiased parameter estimates
(27, 28). Estimates of the ADC (31026 mm2 s21) were determined
from the EPI-DWI data. DCE MRI data were analyzed by incorpo-
rating the Tofts and Kermode pharmacokinetic model, from which
the volume transfer constant (Ktrans, minute21), the rate of ﬂux of
contrast agent into the extracellular extravascular space within a
given volume, was calculated (6).
All data were ﬁtted on a pixel-by-pixel basis using in-house soft-
ware (ImageView, developed in IDL, ITT Visual Information Sys-
tems, Boulder, CO, USA), and the median value of each parameter
determined from a ROI that encompassed either the whole brain,
whole lesion or a portion of the lesion.
Micro computed tomography
Intact heads from Hesx1Cre/1;Ctnnb1lox(ex3)/1 mice and wildtype
control mice were ﬁxed in 10% formalin for at least 48 h, and
patient-derived xenograft-bearing mouse brains were ﬁxed in 4%
formalin, prior to iodination in Lugol’s iodine (I127 concentration of
2.94 3 1024mol/mL) for at least 72 h to improve tissue contrast.
The heads were then rinsed with distilled water to remove excess
iodine, blotted dry and secured within a low density plastic container
covered with polymer ﬁlm to prevent specimen dehydration. Images
were acquired using a Nikon XTH 225 ST micro-(m)-CT scanner,
utilizing a molybdenum X-ray source with anode voltages ranging
between 70 and 100 kV and detector exposure times of 500–708 ms
over 3141 projections (2, 14). Data were reconstructed using
CTPro3D (Nikon Metrology, Tring) and post-processed with VG
Studio MAX software (Volume Graphics GmbH, Heidelberg,
Germany).
Histopathology
Formalin-ﬁxed Hesx1Cre/1;Ctnnb1lox(ex3)/1 mouse tissue imaged by
m-CT was decalciﬁed in 1% formic formaldehyde for 48 h before
embedding in parafﬁn blocks. A further 5 surface decalciﬁcations of
2 h each were performed prior to 5 mm sections being cut in the axial
or sagittal plane, matched to the imaging plane. Sections were then
stained with hematoxylin and eosin (H&E).
The brains from patient-derived xenograft-bearing mice were
formalin-ﬁxed and processed following mCT imaging, and H&E
staining of 3 mm axial sections was performed as previously
described (26).
Slides were scanned using either Nanozoomer (Hamamatsu Pho-
tonics, Welwyn Garden City) or Pannoramic MIDI (3D-Histech,
Sysmex Europe) and processed using CaseViewer 2.0 software
(3D-Histech, Budapest, Hungary).
Statistics
Statistical and survival analysis was performed with GraphPad
Prism 7 (GraphPad Software, La Jolla, CA, USA). The mean of
median values for quantitative MRI parameters were reported and
used for statistical analysis. Results are presented as the mean6 1
standard error of the mean (SEM). Signiﬁcance testing used Stu-
dent’s unpaired t-test and Pearson correlation coefﬁcient (one
tailed) with a 5% conﬁdence level.
RESULTS
Hesx1Cre/1;Ctnnb1lox(ex3)/1 mice develop cystic-
solid tumors with a nonlinear growth pattern
MRI and m-CT imaging performed at 8 weeks of age revealed
enlargement of the pituitary of Hesx1Cre/1;Ctnnb1lox(ex3)/1 mice
relative to wildtype control mice (Figure 1A), consistent with
the previously observed prenatal pituitary hyperplasia (11).
Serial T2-weighted MRI performed every 2 weeks revealed a rel-
atively stable phase with no additional changes detectable, fol-
lowed by lesion enlargement forming a solid tumor with
associated cystic ﬂuid accumulation (hyperintense relative to
midbrain above; Figure 1B) and in most cases hemorrhage (rela-
tively hypointense).
Tumor progression, deﬁned as a change in imaging phenotype
from the stable state, was identiﬁed in thirteen Hesx1Cre/
1;Ctnnb1lox(ex3)/1 mice prior to 1 year of age, at a median age of
17.7 weeks (range 8.3–35.3 weeks, n5 17) (Figure 1C). Median
overall survival in the cohort was found to be 22.6 weeks (range
10.1–41.0 weeks). It was noted that tumors that presented later
appeared to progress more slowly, and indeed the age at which pro-
gression was identiﬁed correlated signiﬁcantly with the time from
progression to sacriﬁce (Pearson r5 0.85, P5 0.0002).
Multiparametric MRI reveals radiological
features similar to human ACP, which correlate
with l-CT and histology
Multiparametric MRI was used to assess the phenotype of progress-
ing Hesx1Cre/1;Ctnnb1lox(ex3)/1 tumors. Considerable heterogeneity
of cystic components, identiﬁed by high T2-weighted signal inten-
sity, was noted both within and between tumors. In a subset of
tumors (n5 5), these cysts remained hyperintense on FLAIR
images, in which the signal from cerebrospinal ﬂuid (CSF) and
other motile ﬂuid compartments would usually be suppressed, and
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were also relatively hyperintense on T1-weighted images (Figure
2A left panel, arrow). In another subset (n5 5) cystic ﬂuid attenu-
ated to the same degree as ventricular CSF on FLAIR and was iso-
intense to the midbrain on T1-weighted images (Figure 2A, center
panel, arrowhead). Both of these cystic phenotypes were also
identiﬁed within individual lesions (n5 3, Figure 2A right panel)
and were consistent with the imaging features of the cysts observed
in ACP patients (10).
Quantitative functional MRI incorporating native and contrast-
enhanced parameters was also performed at study end. Parametric
Figure 1. A. Axial in vivo T2-weighted MRI (upper panel) and ex vivo
micro (m)-CT (lower panel) images of the pituitary region of 8 week old
control and Hesx1Cre/1;Ctnnb1l8x(ex3)/1 mutant mice (each image
acquired from a different mouse). Note the expansion and increased
heterogeneity of the Hesx1Cre/1;Ctnnb1l8x(ex3)/1 pituitaries (solid
arrows) relative to the controls (dashed arrows). Arrowheads indicate
the posterior lobe of pituitary also detectable in l-CT images and *
denotes the sphenoid bone in control mice. MRI resolution 98 3
9831000 mm; m-CT resolution approximately 9 mm isotropic. B. T2-
weighted MRI images of a Hesx1Cre/1;Ctnnb1l8x(ex3)/1 mouse
demonstrating the evolution of a tumor. In this mouse the first
remarkable change was detected at 17.7 weeks, which was followed
by rapid tumor progression including growth of the solid component,
cyst formation and hemorrhage; the mouse was humanely killed at
22.6 weeks according to Home Office regulations. C. Progression-
free and overall survival curves to 1 year of age representing data
from seventeen Hesx1Cre/1;Ctnnb1l8x(ex3)/1 mice alongside the correla-
tion between time to tumor identification and time between identifica-
tion of tumor and death for twelve animals. Pearson correlation
coefficient and one tailed significance analysis.
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ADC maps demonstrated that whilst the solid tumor component
appeared to have a similar ADC to the rest of the brain (Figure
2B), there was substantial heterogeneity in the tumors
corresponding to the different components of the lesions (Figure
2B,C). Quantiﬁcation of ADC in eight end-stage tumors that con-
sisted of all three tumor components showed that ADC was lowest
Figure 2. A. T2-weighted (T2-w), fluid
attenuated inversion recovery (FLAIR) and
T1-weighted (T1-w) MRI images from three
Hesx1Cre/1;Ctnnb1l8x(ex3)/1 mice
demonstrating different cyst imaging
presentation. Arrows denote cystic fluid
that did not attenuate on FLAIR and was
hyperintense on T1-weighted MRI;
arrowheads denote cystic fluid that
attenuated on FLAIR and was isointense
on T1-weighted MRI. The example on the
right shows both cyst phenotypes in the
same tumor. B. Upper panel: T2-
weighted and FLAIR images, and a
parametric map of apparent diffusion
coefficient (ADC) acquired from a 1mm
thick axial slice through a tumor -bearing
Hesx1Cre/1;Ctnnb1l8x(ex3)/1 mouse head.
Lower panel: Matched T1-weighted
images acquired at baseline and 1 minute
after injection of 0.1 mmol/kg Gd-DTPA
and a subtraction map clearly showing
areas of signal enhancement. Green ROI
denotes lesion volume. C. Parametric
maps of ADC and transfer coefficient Ktrans
in the entire lesion and the solid
component of a Hesx1Cre/1;Ctnnb1l8x(ex3)/1
tumor alongside a T2-weighted anatomical
image of the matched 1 mm slice. Green
ROI denotes solid component of the
lesion. Note the heterogeneous signal
enhancement in the solid tumor
components following contrast
administration and high ADC in cystic
areas in B and C.
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in the solid component (6356 29 3 1026 mm2 s21), was signiﬁ-
cantly higher in the hemorrhagic component (8566 79 3 1026
mm2 s21, P5 0.02) and was higher still in the cystic regions
(19536 73 3 1026 mm2 s21, P< 0.0001 vs solid and
hemorrhagic).
The uptake and distribution of Gd-DTPA contrast agent in the
tumors was assessed using two techniques. T1-weighted images
acquired prior to and following contrast agent administration pro-
vided qualitative data that showed heterogeneous signal enhance-
ment in the solid tumor component but no response in the cystic or
hemorrhagic components (Figure 2B). Quantitative maps of the
transfer coefﬁcient Ktrans (Figure 2C), which here represents a com-
pound biomarker of perfusion and permeability, demonstrated het-
erogeneous distribution in the solid tumor component.
Ex vivo m-CT images of intact tumor-bearing Hesx1Cre/
1;Ctnnb1lox(ex3)/1 mouse heads, which had been imaged in vivo by
MRI prior to necropsy, provided higher resolution 3D visualization
of the tumors in situ, conﬁrming the complex architecture observed
on MRI in addition to more detailed evaluation of microcystic com-
ponents within the solid tumor (Figure 3 and Supporting Information
Videos S1 and S2). No invasion of the brain parenchyma by the
tumor was evident, and whilst smaller cysts within the solid tumor
mass were preserved, the integrity of the larger cysts was in some
cases difﬁcult to assess because tissue shrinkage during ﬁxation sepa-
rated the tumor from the brain. H&E stained sections of the decalci-
ﬁed heads showed clinically relevant histological features observed
by MRI and m-CT; for example densely cellular areas of solid tumor,
cysts containing proteinaceous ﬂuid and/or red blood cells, and cyst
walls made up of a simple epithelial layer (Figure 3).
Micro-CT imaging of patient-derived ACP
xenografts reveals the 3D tumor structure and
histological features of human ACP
MRI performed between 124 and 130 days after implantation of
uncultured ACP tumor tissue into the cerebral hemisphere of nude
mice demonstrated successful engraftment, with tumors appearing
heterogeneous on both T2-weighted and post-contrast T1-weighted
images (Figure 4). Ex vivo m-CT of tumor-bearing brains revealed
heterogeneous tumors displaying imaging features that corre-
sponded to histological features commonly observed in human
ACP, such as palisading epithelium, epithelial whorls, stellate retic-
ulum, wet keratin and calciﬁcation (Figure 4 and Supporting Infor-
mation Videos S3–S5). These features were observed to varying
degrees in each of the xenografts.
DISCUSSION
The relevance of preclinical tumor models to human cancer has been
a topic of debate for many years. Transgenic models, in which
expression or knockout of a speciﬁc gene in the native tissue of ori-
gin leads to spontaneously arising tumors, orthotopic xenografts,
where cancer cells are implanted in the organ from which they origi-
nated, and patient-derived xenografts (PDXs), in which human tumor
tissue is implanted directly from surgical or biopsy samples, are
increasingly being exploited. The use of these models for preclinical
cancer research must be underpinned by case-speciﬁc evidence for
each model establishing that tumor development, progression and
radiology recapitulates the human disease. In this study we have
used longitudinal in vivo MRI and high resolution ex vivo l-CT to
compare and contrast the growth patterns and radiological features of
tumors arising in Hesx1Cre/1;Ctnnb1lox(ex3)/1 transgenic mice and in
cerebrally implanted patient-derived ACP xenografts.
MRI was ﬁrst performed when Hesx1Cre/1;Ctnnb1lox(ex3)/1 mice
were approximately 8 weeks of age, where expansion and increased
heterogeneity of the pituitary was observed in comparison with wild-
type control mice. Due to the size of the mouse pituitary (1 mm3
1 mm 3 3 mm) and the resolution achievable with in vivo MRI, it
was not possible to detect the microscopic structural changes previ-
ously described, which were observed in utero as early as 9.5 days
post coitum (11). Micro-CT provided a method for high resolution
Figure 3. In vivo T2-weighted MRI, ex vivo micro (m)-CT and H&E
stained sections from two tumor-bearing Hesx1Cre/1;Ctnnb1l8x(ex3)/1
mouse heads. Snapshots of H&E staining were acquired at 3100
(upper panel) and 3400 (lower panel) magnification. Arrow denotes
densely cellular solid tumor. Small cysts contained proteinaceous fluid
(1) and/or red blood cells (*). Arrowhead indicates the simple epithe-
lial layer that made up the wall of a large cyst. MRI slice thickness
1000 mm, l-CT slice thickness  9 mm, tissue sections 5 mm.
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in situ imaging, achieving resolution of 9mm3, and identiﬁed
altered architecture of the anterior pituitary and also the posterior
lobe of the gland. The high radiation exposure required to acquire
images at this resolution and tissue contrast prohibits the use of this
protocol in vivo and thus for longitudinal studies.
Anatomical T2-weighted MRI provides a non-invasive, non-ioniz-
ing method of monitoring tumor growth over extended periods of
time. In addition, advanced MRI techniques provide a means of
deﬁning non-invasive quantitative biomarkers to inform on biologi-
cally relevant structure-function relationships in tumors (5). Serial
imaging of Hesx1Cre/1;Ctnnb1lox(ex3)/1 mice revealed that, whilst the
pituitary was enlarged from early postnatal life, there was indistin-
guishable growth during a stable period prior to progression, in some
cases rapid, involving solid tumor growth, cystic expansion and other
MRI detectable changes. Progressing tumors were identiﬁed from
8.3 to 35.3 weeks old (median 17.7 weeks), with 4/17 animals not
demonstrating any imaging changes before 1 year of age. Overall
survival, therefore, also differed greatly across the cohort with
median survival being 22.6 weeks (4/17 animals alive beyond 1 year
of age), considerably longer than the previously reported median sur-
vival of 11 weeks, with all animals dying before 6 months of age
(11). These differences are likely the consequence of variations in
the genetic background since the original study was performed. The
time over which tumors progressed was also variable but we show
that the age at which tumor progression was identiﬁed positively cor-
related with the time from progression to sacriﬁce; tumors that took
longer to progress from the steady state, also progressed slower once
expansion was identiﬁed. The molecular mechanisms underpinning
this pattern of tumor evolution require further elucidation.
The formation of cysts is a hallmark in the presentation of ACP
in children (19) and was observed during necropsy in the Hesx1Cre/
1;Ctnnb1lox(ex3)/1 model (11). Here, we show that the proportion
of cystic component varies between tumors, ranging from micro-
cysts within a largely solid lesion, to cysts making up approxi-
mately 70% of the abnormality. Most interestingly, in
approximately half of the tumors analyzed some or all of these
cysts appeared hyperintense on FLAIR images and T1-weighted
images, as is often observed in human ACP (10). This is thought to
be caused by the presence of high levels of protein, cholesterol and
blood breakdown products in the cystic ﬂuid (1, 10, 12), contribut-
ing to its description as “engine oil”. Diffusion-weighed MRI
showed that the ADC of the cystic regions was signiﬁcantly higher
than the other regions of the tumors, demonstrating their ﬂuid-ﬁlled
nature, and ADC values were indistinguishable between cysts that
attenuated on FLAIR images and those that remained hyperintense.
Diffusion-weighted MRI has been investigated, alongside MR
spectroscopy, for the evaluation of ACP in the clinic (25). Calciﬁ-
cation of cyst walls, which is detectable by CT in patients and is
integral in the differential diagnosis of ACP (29), was not observed
in Hesx1Cre/1;Ctnnb1lox(ex3)/1 tumors by ex vivo m-CT, which may
be related to the relatively short evolution time of mouse tumors
compared to human tumors.
The solid component of the tumors, which in some cases did not
enlarge far beyond the original size of the abnormal pituitary, were
in themselves heterogeneous with small areas of hypointensity on
T2-weighted MRI and evidence of microcysts in some cases. These
smaller cysts were also apparent on l-CT and histologically, con-
sistent with some human ACPs (22). As expected, these regions
displayed the most restricted diffusion of water molecules, demon-
strating ADC values equivalent to those measured in the normal
mouse striatum and intracranially implanted murine tumors (5, 23).
Gadolinium contrast agent extravasation occurred heterogeneously
in the solid portion of the tumor only, recapitulating the pattern of
enhancement in patient tumors (10). In patients, some rim
Figure 4. In vivo T2-weighted and gadobutrol-enhanced T1-weighted
MRI acquired immediately prior to necropsy, ex vivo micro (m)-CT and
H&E stained sections from three mice bearing cerebrally implanted
patient-derived ACP xenografts. Histological features from the
patient’s tumor were maintained; cell clusters (#) palisading epithelium
(arrowhead), stellate reticulum (*), calcification (arrows) and wet kera-
tin (1). MRI slice thickness 700 mm, l-CT slice thickness  4–6 mm,
tissue sections 3 mm.
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enhancement in the cysts occurs; this was not observed preclini-
cally but may be a feature of the relatively smaller tumors and rela-
tively lower resolution. Imaging and pathological evidence showed
that, unlike in patients, the tumors that develop in Hesx1Cre/
1;Ctnnb1lox(ex3)/1 mice do not invade into the brain, which is likely
to be as a result of differences in the hypothalamo-pituitary axis
anatomy between mice and humans (18).
The majority of mice (11/13) presented with regions of hypointen-
sity on T2-weighted images, which were either hypointense or isoin-
tense with the brain parenchyma on T1-weighted images, and thus
consistent with the presence of paramagnetic species, such as deoxy-
hemoglobin, ferritin and hemosiderin, from the blood and degrada-
tion of erythrocytes associated with hemorrhage. The size of these
regions varied in size up to approximately 70% of the lesion volume
in the most extreme case. ADC in these regions was signiﬁcantly
higher than in the solid component of the tumors but was approxi-
mately 2.4-fold lower than the ﬂuid in the cysts, suggesting that there
are substantial barriers to the diffusion of water molecules in these
regions. Hemorrhage was also identiﬁable on m-CT images and
H&E staining. The combination of cystic volume and large hemor-
rhagic regions, leading to raised intracranial pressure, was likely the
predominant cause of morbidity in the mouse cohort.
Patient-derived ACP xenografts also showed MRI features simi-
lar to human ACP, consistent with the initial description of the
model (26). In addition, m-CT gave further 3D insight into the
architecture of these tumors, and highlighted several features of
human ACP, including calciﬁcation and speciﬁc histological struc-
tures such as stellate reticulum, wet keratin and palisading epithe-
lium (Figure 4).
As druggable targets are increasingly identiﬁed in human and
mouse studies [reviewed in (3)] it will be important to develop appro-
priate preclinical strategies to test novel therapeutic agents. The two
models described here are complementary and recapitulate many of
the radiological and pathological aspects of human ACP. We antici-
pate that the use of these murine ACP models will improve the accu-
racy of preclinical data and accelerate the development of urgently
required targeted therapies for these devastating human tumors.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online
version of this article at the publisher’s web-site:
Video S1. Micro-CT volume rendering (isotropic voxel
size59.1 mm) demonstrating virtual dissection of the tumor that
arose in the Hesx1Cre/1;Ctnnb1lox(ex3)/1 mouse shown in the
upper panel of Figure 3. Complex areas of cystic and solid
tumor can be identiﬁed, along with compression of the sur-
rounding brain parenchyma.
Video S2. Micro-CT volume rendering (isotropic voxel
size58.7 mm) demonstrating virtual dissection of the tumor that
arose in the Hesx1Cre/1;Ctnnb1lox(ex3)/1 mouse shown in the
lower panel of Figure 3. Complex areas of cystic and solid
tumor can be identiﬁed, along with compression of the sur-
rounding brain parenchyma.
Video S3. Micro-CT volume rendering (isotropic voxel
size53.7 mm) demonstrating virtual dissection of the cerebrally
implanted patient-derived ACP xenograft shown in the upper
panel of Figure 4. High spatial resolution and differential uptake
of iodine-based contrast enables visualization of a cluster within
an area of stellate reticulum.
Video S4. Micro-CT volume rendering (isotropic voxel
size56.1 mm) demonstrating virtual dissection of the cerebrally-
implanted patient-derived ACP xenograft shown in the middle
panel of Figure 4. A radio-dense focus can be seen within the
xenograft; this corresponds to an area of calciﬁcation on histo-
logical examination.
Video S5. Micro-CT volume rendering (isotropic voxel
size53.8 mm) demonstrating virtual dissection of the cerebrally-
implanted patient-derived ACP xenograft shown in the lower
panel of Figure 4. Islands of wet keratin adjacent to solid tumor
(conﬁrmed on H&E, Figure 4) give the xenograft a heterogene-
ous appearance on micro-CT examination.
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